Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAM2020 M2SR H3N2 influenza vaccine + Fluzone HD inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- FluGen
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal, Intramuscular
01
Overview
CAM2020 M2SR H3N2 influenza vaccine + Fluzone HD inactivated influenza vaccine is an investigational combination vaccine regimen being developed by FluGen in collaboration with Sanofi. The regimen consists of FluGen's M2-deficient single-replication (M2SR) intranasal vaccine (specifically the CAM2020 strain derived from A/Cambodia/e0826360/2020) administered alongside Sanofi's Fluzone High-Dose (HD) Quadrivalent, an intramuscular inactivated influenza vaccine. The M2SR component is a live virus vaccine engineered to lack the M2 protein, which allows it to infect host cells and express a broad range of influenza antigens without producing new infectious viral particles. This stimulates both mucosal secretory IgA and cell-mediated immunity. Fluzone HD provides a high-dose systemic antibody response. The combination is designed to enhance protection against influenza in older adults (aged 65-85) by providing both local mucosal and systemic immune responses.
- Brand names
- Fluzone High-Dose Quadrivalent
- Other names
- M2SR + Fluzone HDCam2020 M2SR H3N2 + Fluzone HDM2SR + Fluzone High-Dose
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on CAM2020 M2SR H3N2 influenza vaccine + Fluzone HD inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAM2020 M2SR H3N2 influenza vaccine + Fluzone HD inactivated influenza vaccine.